-+ 0.00%
-+ 0.00%
-+ 0.00%

Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting

Benzinga·10/08/2026 20:24:04
Diffusion vocale

https://www.sec.gov/Archives/edgar/data/34956/000119312526417939/d139658dex991.htm